Home > Oncology > SABCS 2021 > Basic and Translational Research > How tamoxifen can induce uterine cancer

How tamoxifen can induce uterine cancer

Presented By
Dr Kirsten Kübler, Broad Institute, MA, USA
SABCS 2021
Long-term use of tamoxifen is associated with an increased risk for the development of uterine cancer. New research shows that tamoxifen directly activates a signalling pathway (PIK3) that is a well-known driver of uterine cancer development. Tamoxifen is widely used in the adjuvant treatment of oestrogen receptor–positive breast cancer and is an important drug for premenopausal and postmenopausal patients who cannot tolerate aromatase inhibitors. Despite the clear clinical benefit, an adverse effect of tamoxifen is a 2–7-fold increased risk of uterine cancer after 2–5 years of treatment, with further increased risk after 10 years [1]. Dr Kirsten Kübler (Broad Institute, MA, USA) presented results of preclinical research aiming to clarify the mechanism by which tamoxifen increases the risk of uterine cancer and finding approaches to prevent tamoxifen-associated uterine cancer (TA-UC) [2]. Whole-exome sequencing was performed on 21 TA-UC sa...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on